

# CITATION REPORT

List of articles citing

**Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G<sub>0</sub>/G<sub>1</sub> phase of the cell cycle**

**DOI: 10.1016/0277-5379(83)90177-3**

**European Journal of Cancer & Clinical Oncology, 1983, 19, 615-21.**

**Source:** <https://exaly.com/paper-pdf/16381015/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
160	N-desmethyltamoxifen inhibits growth of MCF 7 human mammary carcinoma cells in vitro. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1983</b> , 19, 1179-81		8
159	Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1983</b> , 19, 307-18		79
158	Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7. <b>1984</b> , 49, 717-22		40
157	Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1984</b> , 20, 1419-24		91
156	The antiproliferative effect of tamoxifen in breast cancer cells: mediation by the estrogen receptor. <b>1984</b> , 35, 89-96		61
155	Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. <b>1984</b> , 20, 111-20		92
154	Anti-proliferative effects of 1,2-diphenylethane oestrogens and anti-oestrogens on human breast cancer cells. <b>1985</b> , 110, 17-24		4
153	Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites. <i>Breast Cancer Research and Treatment</i> , <b>1985</b> , 5, 231-43	4.4	96
152	Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1985</b> , 21, 1493-9		51
151	Effect of tamoxifen on the receptor-positive T61 and the receptor-negative T60 human breast carcinomas grown in nude mice. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1985</b> , 21, 1349-54		24
150	Modulation of oestrogen excretion profiles by adjuvant chemotherapy in pre- and postmenopausal breast cancer. <b>1985</b> , 23, 1115-22		4
149	Estrogen induced expansion of the growth fraction in receptor negative human breast cancer. <b>1985</b> , 23, 1169-72		6
148	Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor. <b>1986</b> , 140, 523-9		45
147	Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity. <b>1986</b> , 35, 4463-5		119
146	Role of estrogens in the malignant progression of breast cancer: new perspectives. <b>1986</b> , 7, 294-296		8
145	Microsomal binding sites for antioestrogens in rat liver. Properties and detergent solubilization. <b>1986</b> , 236, 903-11		20
144	Molecular expression of epitopes recognized by monoclonal antibodies HMFG-1 and HMFG-2 in human breast cancers: diversity, variability and relationship to prognostic factors. <b>1986</b> , 38, 89-96		21

143	Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. <b>1987</b> , 27, 891-7		63
142	Epidermal growth factor partially reverses the inhibitory effects of antiestrogens on T 47D human breast cancer cell growth. <b>1987</b> , 146, 739-45		49
141	In vitro effects of tamoxifen on UM-SCC head and neck cancer cell lines: correlation with the estrogen and progesterone receptor content. <b>1987</b> , 39, 77-81		21
140	Mode of estrogen action on cell proliferation in CAMA-1 cells: II. Sensitivity of G1 phase population. <i>Journal of Cellular Biochemistry</i> , <b>1987</b> , 34, 213-25	4-7	43
139	Effect of tamoxifen upon cell DNA analysis by flow cytometry in primary carcinoma of the breast. <b>1987</b> , 55, 561-6		9
138	The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. <i>Breast Cancer Research and Treatment</i> , <b>1988</b> , 11, 197-209	4-4	106
137	Effects of tamoxifen and 4-hydroxytamoxifen on synchronized cultures of the human breast cancer cell line MCF-7. <i>Breast Cancer Research and Treatment</i> , <b>1988</b> , 11, 37-43	4-4	4
136	In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen. <b>1988</b> , 30, 228-38		24
135	The clinical biology of hormone-responsive breast cancer. <b>1988</b> , 15, 33-51		14
134	Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations. <b>1988</b> , 6, 589-95		80
133	Effects of oestrogen on human breast cancer cells in culture. <b>1989</b> , 95, 119-132		2
132	Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. <b>1989</b> , 2, 225-34		96
131	The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. <b>1989</b> , 9, 614-20		122
130	Characterisation of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and ability of the resistant phenotype. <b>1989</b> , 59, 522-6		37
129	Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. <b>1989</b> , 60, 223-6		56
128	Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1989</b> , 25, 57-63		57
127	Cytostatic effect of antiestrogens in lymphoid cells: relationship to high affinity antiestrogen-binding sites and cholesterol. <b>1989</b> , 1014, 162-72		18
126	Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. <b>1989</b> , 37, 451-90		122

125	Endocrine characterization of a human ovarian carcinoma (BG-1) established in nude mice. <i>Steroids</i> , <b>1989</b> , 54, 593-606	2.8	11
124	Steroids and steroid receptors in growth control of cultured breast cancer cells. <b>1990</b> , 5, 67-75		34
123	Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells. <b>1990</b> , 55, 159-63		8
122	Mechanisms of growth regulation of human breast cancer. <b>1990</b> , 4, 51-66		3
121	Tamoxifen binding sites heterogeneity in breast cancer: a comparative study with steroid hormone receptors. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1991</b> , 27, 452-6		12
120	Differential regulation of c-myc by progestins and antiestrogens in T-47D human breast cancer cells. <b>1991</b> , 39, 39-44		32
119	Synergy between preactivated photofrin-II and tamoxifen in killing retrofibroma, pseudomyxoma and breast cancer cells. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1991</b> , 27, 1034-9		11
118	Keynote address: integration of cytostatic agents and radiation therapy: a different approach to "proliferating" human tumors. <b>1991</b> , 20, 295-302		23
117	Effects of melatonin on the cell cycle kinetics and "estrogen-rescue" of MCF-7 human breast cancer cells in culture. <b>1991</b> , 10, 36-42		135
116	New hormonal approaches to the treatment of breast cancer. <b>1991</b> , 11, 29-41		9
115	Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor. <i>Breast Cancer Research and Treatment</i> , <b>1991</b> , 19, 47-56	4.4	19
114	Proliferative inhibition of human breast carcinoma cells by high concentration estradiol does not alter radiosensitivity. <i>Breast Cancer Research and Treatment</i> , <b>1991</b> , 18, 141-8	4.4	11
113	A 23-pS Ca <sup>2+</sup> (+)-activated K <sup>+</sup> channel in MCF-7 human breast carcinoma cells: an apparent correlation of channel incidence with the rate of cell proliferation. <b>1991</b> , 417, 562-70		30
112	Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. <b>1992</b> , 55, 1-30		34
111	Mechanisms of growth inhibition by antiestrogens and progestins in human breast and endometrial cancer cells. <b>1992</b> , 43, 117-21		18
110	Opposite regulation of cAMP concentration in the quail oviduct and the mouse uterus by tamoxifen. Correlation with estrogen-antagonist and estrogen-agonist activity. <b>1992</b> , 41, 571-7		7
109	Comparative affinity of steroidal and non-steroidal antioestrogens, cholesterol derivatives and compounds with a dialkylamino side chain for the rat liver antioestrogen binding site. <b>1992</b> , 43, 2511-8		16
108	Vitellogenin synthesis in cultured hepatocytes; an in vitro test for the estrogenic potency of chemicals. <b>1993</b> , 44, 263-72		234

107	The anti-estrogen tamoxifen blocks the stimulatory effects of interleukin-6 on 17 beta-hydroxysteroid dehydrogenase activity in MCF-7 cells. <b>1993</b> , 46, 605-11		14
106	Cell cycle kinetic effects of tamoxifen on human breast cancer cells. Flow cytometric analyses of DNA content, BrdU labeling, Ki-67, PCNA, and statin expression. <b>1993</b> , 698, 174-81		13
105	Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , <b>1994</b> , 31, 95-105	4.4	100
104	Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. <b>1994</b> , 17, 25-32		65
103	Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen. <b>1994</b> , 70, 1211-6		9
102	Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. <i>European Journal of Cancer</i> , <b>1994</b> , 30A, 1663-9	7.5	54
101	Preclinical data for Droloxifene. <b>1994</b> , 84, 101-16		63
100	Speculation on the mechanism of action of triphenylethylene antioestrogens. <b>1994</b> , 47, 1927-37		27
99	Antagonism between tamoxifen and doxorubicin in the MCF-7 human breast tumor cell line. <b>1994</b> , 47, 1449-52		27
98	Clonal dominance between subpopulations of mixed small cell lung cancer xenografts implanted ectopically in nude mice. <i>European Journal of Cancer</i> , <b>1995</b> , 31A, 222-9	7.5	6
97	Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines. <b>1995</b> , 35, 511-8		14
96	Cell proliferation in dimethylbenz(A)anthracene(DMBA)-induced rat mammary carcinoma treated with antiestrogen toremifene. <b>1995</b> , 34, 479-85		7
95	Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. <b>1996</b> , 35, 1011-9		49
94	Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases. <b>1996</b> , 73, 735-43		30
93	Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. <b>1996</b> , 122, 603-12		64
92	Cell cycle expression of estrogen receptors determined by image analysis on human breast cancer cells in vitro and in vivo. <i>Breast Cancer Research and Treatment</i> , <b>1996</b> , 39, 147-54	4.4	7
91	Cell cycle expression of steroid receptors determined by image analysis on human breast cancer cell line: a hypothesis on the effects of antiestrogens. <i>Breast Cancer Research and Treatment</i> , <b>1996</b> , 37, 77-87	4.4	16
90	Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. <b>1997</b> , 17, 4059-69		224

89	Ultrastructural study of anti-tumor effects of tamoxifen in two malignant melanoma patients. <b>1997</b> , 24, 441-50	2
88	The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. <b>1997</b> , 75, 804-9	26
87	The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>1997</b> , 44, 123-33	4-4 49
86	Different points of action of retinoids and anti-estrogens in G1 phase identified in synchronized T-47D breast cancer cells. <b>1997</b> , 70, 291-6	9
85	Tamoxifen inhibits colorectal cancer metastases in the liver: a study in a murine model. <b>1998</b> , 13, 521-7	16
84	Chemoprevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination. <b>1998</b> , 89, 487-95	42
83	New antiestrogens in breast cancer: a review. <b>1998</b> , 4, 213-29	2
82	Behaviour of vaginal epithelial maturation and sex hormone binding globulin in post-menopausal breast cancer patients during the first year of tamoxifen therapy. <b>1998</b> , 9, 263-70	9
81	Aryl hydrocarbon receptor-mediated antiestrogenicity in MCF-7 cells: modulation of hormone-induced cell cycle enzymes. <b>1998</b> , 356, 239-48	74
80	Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. <b>1999</b> , 13, 969-80	56
79	Ribozyme-mediated cleavage of the estrogen receptor messenger RNA and inhibition of receptor function in target cells. <b>1999</b> , 13, 925-34	6
78	Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. <b>1999</b> , 13, 1373-87	149
77	Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen. <b>1999</b> , 32, 289-302	25
76	Influence of antiestrogens on EGF- and IGF-I-mediated proliferation of human breast cancer cells. <b>1999</b> , 35, 19-21	5
75	The evolving role of specific estrogen receptor modulators (SERMs). <b>1999</b> , 8, 103-23	19
74	Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain. <b>2000</b> , 19, 4746-53	18
73	Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. <b>2000</b> , 97, 9042-6	199
72	Electrostatic interactions of androgens and progesterone derivatives with rainbow trout estrogen receptor. <b>2000</b> , 75, 129-37	10

71	Chemically induced rat mammary tumor treated with tamoxifen showed decreased expression of cyclin D1, cyclin E, and p21(Cip1). <b>2001</b> , 170, 109-16		8
70	TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTS. <b>2001</b> , 97, 855-866		57
69	Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 931-42	2.2	217
68	The Brn-3b POU family transcription factor regulates the cellular growth, proliferation, and anchorage dependence of MCF7 human breast cancer cells. <b>2001</b> , 20, 4961-71		28
67	Relationship Between Expression of Coactivators and Corepressors of Hormone Receptors and Resistance of Ovarian Cancers to Growth Regulation by Steroid Hormones. <b>2001</b> , 8, 104-113		7
66	Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 23763-8	5.4	108
65	The cyclin-dependent kinase inhibitor p21WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 5145-52	5.4	28
64	Tamoxifen ("Nolvadex"): a review. <b>2002</b> , 28, 165-80		171
63	Selective estrogen receptor modulators (SERM) for the brain: Recent advances and remaining challenges for developing a NeuroSERM. <b>2002</b> , 56, 380-392		10
62	Potential of antiproliferative effects of tamoxifen and ethanol on mouse hepatoma cells by melatonin: possible involvement of mitogen-activated protein kinase and induction of apoptosis. <b>2002</b> , 33, 8-13		15
61	The anti-epidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves anti-hormone response and prevents development of resistance in breast cancer in vitro. <b>2003</b> , 144, 5105-17		147
60	Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1823-31	9.7	67
59	Synergistic interactions between tamoxifen and trastuzumab (Herceptin). <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 1409-20	12.9	68
58	CCAAT/Enhancer binding protein delta (c/EBPdelta) regulation and expression in human mammary epithelial cells: I. "Loss of function" alterations in the c/EBPdelta growth inhibitory pathway in breast cancer cell lines. <i>Journal of Cellular Biochemistry</i> , <b>2004</b> , 93, 830-43	4.7	35
57	From ligand structure to biological activity: modified estratrienes and their estrogenic and antiestrogenic effects in MCF-7 cells. <i>Steroids</i> , <b>2004</b> , 69, 401-18	2.8	26
56	Cáncer uterino en pacientes tratadas con tamoxifeno por un cáncer de mama. <i>Clinica E Investigacion En Ginecologia Y Obstetricia</i> , <b>2005</b> , 32, 204-208	0	
55	Efectos del tamoxifeno en el epitelio vaginal y los ovarios. <i>Progresos En Obstetricia Y Ginecologia</i> , <b>2006</b> , 49, 66-71	0	
54	Enhancement of docetaxel efficacy in head and neck cancer treatment by G0 cell stimulation. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 1502-7	7.5	10



53	Tamoxifen. <b>2007</b> , 83-102		1
52	Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells. <i>Cellular Signalling</i> , <b>2007</b> , 19, 1290-300	4.9	26
51	G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells. <i>Human Cell</i> , <b>2008</b> , 21, 28-37	4.5	19
50	The marriage of growth factor inhibitors and chemotherapy: bliss or bust?. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1545-8	2.2	8
49	Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. <i>Lancet, The</i> , <b>2009</b> , 374, 2055-2063	4.0	193
48	Anti-apoptotic effect of claudin-1 in tamoxifen-treated human breast cancer MCF-7 cells. <i>BMC Cancer</i> , <b>2010</b> , 10, 548	4.8	32
47	Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. <i>Breast Cancer Research</i> , <b>2010</b> , 12, R62	8.3	34
46	Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance. <i>Translational Oncology</i> , <b>2011</b> , 4, 293-300	4.9	19
45	Tamoxifen lowers the MMP-9/TIMP-1 ratio and inhibits the invasion capacity of ER-positive non-small cell lung cancer cells. <i>Biomedicine and Pharmacotherapy</i> , <b>2011</b> , 65, 525-8	7.5	15
44	Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. <i>Breast Cancer Research</i> , <b>2011</b> , 13, R52	8.3	118
43	Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 128, 69-78	4.4	44
42	Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. <i>Endocrine-Related Cancer</i> , <b>2011</b> , 18, 333-45	5.7	202
41	Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. <i>Endocrine-Related Cancer</i> , <b>2011</b> , 18, C19-24	5.7	99
40	Anti-breast cancer potential of daidzein in rodents. <i>Life Sciences</i> , <b>2012</b> , 91, 415-9	6.8	48
39	Tamoxifen-loaded thiolated alginate-albumin nanoparticles as antitumoral drug delivery systems. <i>Journal of Biomedical Materials Research - Part A</i> , <b>2012</b> , 100, 1467-76	5.4	41
38	Histone deacetylase inhibitors equipped with estrogen receptor modulation activity. <i>Journal of Medicinal Chemistry</i> , <b>2013</b> , 56, 5782-96	8.3	64
37	MCF-7 cells--changing the course of breast cancer research and care for 45 years. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	107
36	PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 369ra175	17.5	35



35	Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 17	8.3	195
34	CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 1657-67	4	10
33	The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro. <i>Breast Cancer</i> , <b>2017</b> , 24, 658-666	3.4	9
32	Opportunities and challenges of long term anti-estrogenic adjuvant therapy: treatment forever or intermittently?. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 297-310	3.5	3
31	Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2225-2232	10.3	43
30	Cell cycle-dependent force transmission in cancer cells. <i>Molecular Biology of the Cell</i> , <b>2018</b> , 29, 2528-2539	3.5	21
29	Protective effects of <i>Vitis vinifera</i> (grapes) and one of its biologically active constituents, resveratrol, against natural and chemical toxicities: A comprehensive review. <i>Phytotherapy Research</i> , <b>2018</b> , 32, 2164-2190	6.7	32
28	Radiosensitivity: Gender and Order of Administration of G-CSF, An Experimental Study in Mice. <i>Radiation Research</i> , <b>2019</b> , 191, 335-341	3.1	0
27	Potentiating the anti-cancer profile of tamoxifen-loaded graphene using deep eutectic solvents as functionalizing agents. <i>Applied Nanoscience (Switzerland)</i> , <b>2020</b> , 10, 293-304	3.3	9
26	MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 2	7.8	3
25	Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 190, 19-38	4.4	5
24	Steroidal regulation of cell cycle progression. <i>Novartis Foundation Symposium</i> , <b>1995</b> , 191, 218-28; discussion 228-34		1
23	Tamoxifen Metabolism and Oestrogen Receptor Function - Implications for Mechanisms of Resistance in Breast Cancer. <b>1996</b> , 231-266		1
22	Antiestrogen Therapy for Breast Cancer. <i>Cancer Treatment and Research</i> , <b>1988</b> , 97-110	3.5	5
21	Altering cell kinetics with endocrine therapy. <i>Cancer Treatment and Research</i> , <b>1992</b> , 60, 293-313	3.5	1
20	Steroidal pure antiestrogens. <i>Cancer Treatment and Research</i> , <b>1991</b> , 239-257	3.5	9
19	Steroids, growth factors, and cell cycle controls in breast cancer. <i>Cancer Treatment and Research</i> , <b>1991</b> , 53, 305-31	3.5	14
18	Current Concepts of Tumor Promotion by Phorbol Esters and Related Compounds. <b>1986</b> , 261-274		2

17	Modulation of the Estrogen Response Pathway in Human Breast Cancer Cells by Melatonin. <b>2001</b> , 343-358		4
16	The Actions of Steroid Hormones on Animal Cells in Culture: Mechanisms and Applications. <b>1994</b> , 161-195		1
15	Microsomal binding sites for nonsteroidal anti-estrogens in MCF 7 human mammary carcinoma cells. Demonstration of high affinity and narrow specificity for basic ether derivatives of triphenylethylene.. <i>Journal of Biological Chemistry</i> , <b>1984</b> , 259, 4223-4229	5.4	49
14	The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 218-28	15.9	152
13	Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression. <i>PLoS ONE</i> , <b>2010</b> , 5, e11011	3.7	36
12	MOLECULAR PHARMACOLOGY OF TAMOXIFEN; AN ANTIESTROGEN WITH ANTITUMOR PROPERTIES IN ANIMALS AND MAN. <b>1985</b> , 603-636		1
11	Endocrine Control of Breast Development. <b>2004</b> , 49-88		
10	Tamoxifen Goes Forward Alone. <i>Milestones in Drug Therapy</i> , <b>2013</b> , 31-46		
9	Heterogeneity of Binding Sites for Triphenylethylene Antiestrogens in Estrogen Target Tissues. <b>1984</b> , 49-65		
8	Cytokinetics of Mammary Tumor Models and the Effect of Therapeutic Intervention. <b>1987</b> , 453-478		
7	Therapie des metastasierenden Mammakarzinoms. <i>Angewandte Onkologie</i> , <b>1992</b> , 132-152		
6	Rationalizing Optimal Timing for Adjuvant Hormone Therapy for Patients with Breast Cancer: Impact on Limited Resource Countries. <i>International Journal of Clinical Medicine</i> , <b>2016</b> , 07, 419-432	0.3	
5	Adjuvant Systemic Therapy: Endocrine Therapy. <b>2016</b> , 99-130		
4	Adjuvant Systemic Therapy: Endocrine Therapy. <b>2019</b> , 103-127		
3	p27 Regulation by Estrogen and Src Signaling in Human Breast Cancer. <b>2008</b> , 89-97		1
2	The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer.. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 785796	5.7	0
1	Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers. <b>2023</b> , 211-232		0